Study for the effect of traditional Chinese medicine on the enhancement and attenuation of local advanced non-small cell lung cancer during radiotherapy and chemotherapy

Shanghai Pulmonary Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Patients with locally advanced non-small cell lung cancer confirmed by pathology, who are not suitable for surgery and can accept radiotherapy and chemotherapy;
•2. Patients aged 18-70 years old with ECoG PS 0-1 and expected survival time >=6 months;
•3. For patients without major organ dysfunction and with basically normal heart, liver and kidney functions, the test indexes meet the following requirements: blood: leukocyte >4.0x10^9/L, neutrophil absolute value > 1.5x10^9/L, platelet count >100x10^9/L, hemoglobin >110g/L; liver function: serum bilirubin is 1.5 times lower than the maximum normal value; ALT and AST are 1.5 times lower than the maximum normal value; bun. Cr is within the normal range;
•4. Pulmonary function: FEV1 >45%, DLCO >60% before treatment;
•5. Patients without other cancers except stage I cervical cancer and skin basal cell carcinoma;
•6. Patients with good compliance who can understand the situation of this study and sign the informed consent.

•1. Patients with any acute or chronic diseases that are not suitable for radiotherapy and chemotherapy;
•2. Patients with previous cancer history other than stage I cervical cancer and skin basal cell carcinoma, or who have undergone lobectomy or pneumonectomy;
•3. Patients with active systemic infection or pulmonary or pericardial infection;
•4. Pregnant or lactating women;
•5. Patients with poor compliance with the protocol are not suitable for the study.

发起方